Strategic hires Symeres has recently appointed a new Chief Scientific Officer and CFO, signaling an emphasis on scientific leadership and financial discipline to support growth and expanding collaboration opportunities.

Expansion through partnerships Recent collaborations and acquisitions, including a tie-up with Ambagon Therapeutics and the acquisition of DGr Pharma, indicate a strategy to broaden discovery capabilities and scale CDMO/CRO offerings.

Transatlantic scale With transatlantic teams and over 30 years of experience, Symeres is positioned to offer cross-border development services, regulatory strategy, and manufacturing support to global pharma players seeking integrated solutions.

Small molecule focus The company specializes in small molecule drug development, spanning discovery to GMP manufacturing, presenting opportunities to engage with clients seeking end-to-end CRO/CDMO support in medicinal chemistry, ADME-Tox, process development, and CMC.

Financial growth signals Revenues in the product range of one to ten million and ongoing leadership hires suggest active growth, offering potential upsell opportunities for expanded services, dedicated project management, and long-term manufacturing contracts.